Piramal Pharma Ltd

Piramal Pharma Ltd (PPLPHARMA) has emerged as one of the most actively traded stocks in the Pharmaceuticals & Biotechnology sector, registering a remarkable surge in trading volume and price performance. Despite a recent downgrade in its Mojo Grade to Sell, the stock has demonstrated strong investor interest, outperforming its sector and broader market indices over the past two days.

Piramal Pharma Ltd (PPLPHARMA) emerged as one of the most actively traded stocks by value on 23 June 2026, registering a significant 10.12% gain in a single day. The small-cap pharmaceutical company witnessed robust investor participation, with total traded volume exceeding 1.7 crore shares and a turnover nearing ₹289.46 crores, signalling renewed interest from institutional and retail investors alike.

Piramal Pharma Ltd (PPLPHARMA) witnessed a remarkable surge in trading volume on 23 Jun 2026, with over 1.7 crore shares changing hands, marking one of the highest volume days in recent months. The stock outperformed its sector and broader market indices, signalling renewed investor interest following a five-day decline.

The Sensex edged up a modest 0.05% on 23 Jun 2026, while Piramal Pharma Ltd surged 8.73%, hitting an intraday high of Rs 173.9. This 6.93-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a distinctly stock-specific rally rather than a broad market lift.

Piramal Pharma Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 15 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Piramal Pharma Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 04 June 2026, providing investors with the latest insights into its performance and outlook.

Piramal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Piramal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Piramal Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent day gain of 2.39% to close at ₹184.05, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on the stock’s near-term trajectory.

Piramal Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade to a Sell rating, the stock’s mixed technical profile and relative outperformance over various time frames warrant a detailed analysis for investors navigating the Pharmaceuticals & Biotechnology sector.

Piramal Pharma Ltd (PPLPHARMA) has emerged as one of the most actively traded stocks on 7 May 2026, registering a remarkable surge in volume and price amidst heightened volatility. The pharmaceutical and biotechnology small-cap stock outperformed its sector and broader market indices, signalling strong investor interest despite a recent downgrade in its mojo grade from Hold to Sell.

Piramal Pharma Ltd (PPLPHARMA) emerged as one of the most actively traded stocks by value on 7 May 2026, registering a remarkable 12.39% intraday gain and outperforming its sector by over 14%. The pharmaceutical small-cap has attracted significant institutional interest, with trading volumes soaring to nearly 3 crore shares and a total traded value exceeding ₹551 crore, signalling heightened investor participation amid volatile market conditions.

The Sensex declined 0.18% on 7 May 2026, while Piramal Pharma Ltd surged 8.42%, outperforming its Pharmaceuticals & Biotechnology sector by 6.05 percentage points. This sharp single-session gain stands out as a stock-specific event amid a broadly weak market backdrop.

Piramal Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish signals on weekly charts, monthly indicators suggest caution, reflecting a complex interplay of momentum and trend signals that investors should carefully analyse.

Piramal Pharma Ltd’s latest quarterly results for March 2026 reveal a shift from previously positive financial trends to a flat performance, despite notable growth in net sales and profit before tax. The company’s financial health presents a complex picture, with strong operational metrics contrasting with subdued returns and elevated leverage, prompting a downgrade in its Mojo Grade to Sell.

Piramal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Piramal Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent dip in share price and ongoing sector headwinds. This change reflects a significant reappraisal of the company’s price-to-earnings and price-to-book value metrics relative to its historical averages and peer group, signalling potential opportunities for investors amid a challenging pharmaceuticals and biotechnology landscape.